J
Jesse J. Waggoner
Researcher at Emory University
Publications - 123
Citations - 3191
Jesse J. Waggoner is an academic researcher from Emory University. The author has contributed to research in topics: Medicine & Dengue virus. The author has an hindex of 26, co-authored 89 publications receiving 2164 citations. Previous affiliations of Jesse J. Waggoner include Stanford University & Emory Healthcare.
Papers
More filters
Journal ArticleDOI
Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus
Jesse J. Waggoner,Lionel Gresh,Maria José Vargas,Gabriela Ballesteros,Yolanda Tellez,K. James Soda,Malaya K. Sahoo,Andrea Nuñez,Angel Balmaseda,Eva Harris,Benjamin A. Pinsky +10 more
TL;DR: Zika virus, chikungunya virus, and dengue virus result in similar clinical presentations, and coinfections may be relatively common.
Journal ArticleDOI
Zika Virus: Diagnostics for an Emerging Pandemic Threat
TL;DR: This minireview details the methods that are available to diagnose ZIKV infection and describes how to identify the mosquito-borne Zika virus infection.
Journal ArticleDOI
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
Venkata Viswanadh Edara,Carson Norwood,Katharine Floyd,Katharine Floyd,Lilin Lai,Lilin Lai,Meredith E. Davis-Gardner,Meredith E. Davis-Gardner,William H. Hudson,Grace Mantus,Lindsay E. Nyhoff,Max W. Adelman,Rebecca Fineman,Shivan N. Patel,Rebecca Byram,Dumingu Nipuni Gomes,Garett Michael,Hayatu Abdullahi,Nour Beydoun,Bernadine Panganiban,Nina N. McNair,Kieffer Hellmeister,Jamila Pitts,Joy Winters,Jennifer Kleinhenz,Jacob Usher,James B O'Keefe,Anne Piantadosi,Jesse J. Waggoner,Ahmed Babiker,David S. Stephens,Evan J. Anderson,Srilatha Edupuganti,Nadine Rouphael,Rafi Ahmed,Jens Wrammert,Mehul S. Suthar +36 more
TL;DR: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B. 1.1, suggesting that protective humoral immunity may be retained against this variant.
Journal ArticleDOI
Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Timothy N. Hoang,Maria Pino,Arun K. Boddapati,Elise G. Viox,Carly E. Starke,Amit A. Upadhyay,Sanjeev Gumber,Sanjeev Gumber,Michael Nekorchuk,Kathleen Busman-Sahay,Zachary Strongin,Justin L. Harper,Gregory K. Tharp,Kathryn L. Pellegrini,Shannon Kirejczyk,Keivan Zandi,Sijia Tao,Tristan R. Horton,Elizabeth N. Beagle,Ernestine A. Mahar,Michelle Y.H. Lee,Joyce Cohen,Sherrie Jean,Jennifer S. Wood,Fawn Connor-Stroud,Rachelle L. Stammen,Olivia M. Delmas,Shelly Wang,Kimberly A. Cooney,Michael N. Sayegh,Lanfang Wang,Peter D. Filev,Daniela Weiskopf,Guido Silvestri,Guido Silvestri,Jesse J. Waggoner,Anne Piantadosi,Sudhir Pai Kasturi,Hilmi Al-Shakhshir,Susan Pereira Ribeiro,Rafick Pierre Sekaly,Rebecca D. Levit,Jacob D. Estes,Jacob D. Estes,Thomas H. Vanderford,Raymond F. Schinazi,Steven E. Bosinger,Steven E. Bosinger,Mirko Paiardini,Mirko Paiardini +49 more
TL;DR: A beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection are elucidated.
Journal ArticleDOI
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Venkata Viswanadh Edara,Kelly E. Manning,Madison Ellis,Lilin Lai,Kathryn Moore,Stephanie L. Foster,Katharine Floyd,Meredith E. Davis-Gardner,Grace Mantus,Lindsay E. Nyhoff,Sarah Bechnak,Ghina Alaaeddine,Amal Naji,Hady Samaha,Matthew Lee,Laurel Bristow,Matthew Gagne,Jesmine Roberts-Torres,Amy R. Henry,Sucheta Godbole,Arash Grakoui,Marybeth Saxton,Anne Piantadosi,Jesse J. Waggoner,Daniel C. Douek,Nadine Rouphael,Jens Wrammert,Mehul S. Suthar +27 more
TL;DR: BadBaden et al. as discussed by the authors used serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay, and they showed that a third dose is required to provide robust neutralizing antibody responses against the Omicron variant.